HLA-DQ2 Binding Compounds for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases associated with HLA class II, DQ2, and DQ8 alleles, such as celiac disease and Type 1 Diabetes, are inadequate, leading to significant health burdens and quality of life issues due to the lack of effective and safe methods for preventing or slowing disease progression.
Innovation Solution
Development of compounds that inhibit the binding of antigens to HLA-DQ2 and DQ8 molecules on antigen-presenting cells, thereby blocking T cell activation and reducing autoimmune responses, using specific chemical structures that occupy the peptide binding groove of these molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases are used, then disease symptoms can be managed, but quality of life deteriorates and safety issues arise
Solution Approach 1:
The patent introduces small organic molecules as intermediary compounds that specifically bind to HLA-DQ2 and HLA-DQ8 molecules, blocking the interaction between these molecules and gluten-derived peptides. This intermediary mechanism prevents the harmful immune response without requiring complete gluten elimination, thereby maintaining treatment effectiveness while improving quality of life by allowing patients to tolerate certain gluten-containing foods.
2Reliability
If gluten-free diet is imposed, then celiac disease symptoms improve, but adherence becomes difficult and quality of life decreases
Solution Approach 1:
The small organic molecules act as pharmacological intermediaries that replicate the protective effect of a gluten-free diet by blocking the HLA-DQ2/8-gliadin interaction. This allows patients to maintain a more normal diet with improved adherence, while still achieving disease control comparable to strict gluten elimination.
Solution Approach 2:
The invention changes the therapeutic parameter from dietary restriction (behavioral parameter) to pharmacological intervention (chemical parameter). By administering small organic molecules that modify the immune recognition pathway, the treatment transforms the challenge of dietary adherence into a manageable medication regimen with predictable dosing and monitoring.
3Reliability
If HLA-DQ2 and HLA-DQ8 molecules present antigens to T cells, then immune response is activated, but autoimmune damage occurs
Solution Approach 1:
The patent converts the harmful autoimmune response into a beneficial protective mechanism by using small organic molecules to block the specific pathological interaction between HLA-DQ2/8 and gluten peptides. This selective blocking preserves the overall functionality of the MHC class II system for presenting other antigens, while eliminating the harmful autoimmunity. The harmful autoantibody response is thus converted into a targeted therapeutic intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively prevent or slow the development of autoimmune diseases by blocking antigen presentation to T cells, potentially offering a safer and more effective alternative to existing treatments by preserving intestinal mucosal barriers and delaying disease onset.
Implementation Method 1
using specific chemical structures that occupy the peptide binding groove of these molecules
Data Source
AI summary
Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.